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Abstract 
 Elizabethkingia anophelis is a beta-lactam antibiotic resistant bacterium that uses a 
variety of mechanisms to express this resistance. It is currently unknown how E. anophelis 
responds when exposed to different beta-lactam antibiotics and what genes will up or down 
regulate different genes in order to express antibiotic resistance. When exposed to cefotaxime it 
appears that E. anophelis will up regulate the production of 4 putative RND efflux pumps along 
with slight up regulation of a single putative peptidoglycan synthesis protein. This is done in 
conjunction with a relevant increase fold change in the beta-lactamase BlaB by a factor of +1.5 
and an average decreases of -2.33 in the production of GOB, CME, and putative beta-lactamases 
TLA and Open Reading frame 666. However, when exposed to imipenem E. anophelis will 
instead down regulate the production of RND efflux pumps, and slightly up regulate the 
production of a single peptidoglycan synthesis protein. This combined with a decrease in 
production of BlaB and CME and a relevant increase GOB and ORF666. Both GOB and 
ORF666 increased by an average fold change of +2.1 with a mRNA count increase of +1,552 
leads to a unique response. This difference in the change in the expression of beta-lactamases, 
peptidoglycan synthesis and efflux pumps under cefotaxime and imipenem conditions shows 
different responses within a cell to when reaction with different beta-lactam antibiotics.  Finally, 
the observed response by ORF666 suggests that this putative beta-lactamase may play an 
important role in the resistance of E. anophelis to imipenem, and future work is needed to 
establish if this is a functional beta-lactamase. 
Introduction 
Elizabethkingia anophelis is an important emerging opportunistic human pathogen with 
mortality rate of around 25%,1 and is known to cause meningitis, bloodstream, and respiratory 
infections in young children and immunocompromised individuals.1 Infections caused by E. 
anophelis are also notable because they can be passed from an infected mother to a newborn 
child and can cause neonetal meningitis.2,3 Elizabethkingia anphelis has a low rate of infection 
and typically infects around 5-10 individuals in the United States per year.4 However, outbreaks 
have occurred around the world in places such as Wisconsin, Michigan, Illinois, China, and the 
Central African Republic.3,5  In the midwestern US outbreak (2016) 63 individuals were infected 
by E. anophelis and 18 of those patients died (28.5% mortality).4 This high mortality rate of  E. 
anophelis is due to combination of antibiotic resistance to multiple drugs lack of knowledge of 
the species, and the immunocompromised status of infected individuals. These factors combined 
have led to ineffective treatment options and have caused E. anophelis to be clinically relevant 
for research.  
In order to obtain a further understanding we will be focusing on the identifying the 
possible mechanisms of antibiotic resistance to beta-lactam antibiotics. Under normal conditions 
beta-lactam antibiotics work to disrupt and destroy the synthesis of the cell wall of bacteria. 6 
This is done by inhibiting cell wall synthesis proteins, known as penicillin binding proteins 
(PBP). Inhibition of these enzymes causes the cell to be unable to replace and repair the 
peptidoglycan cell wall and causes eventual lysis of the cell. 7 However, multiple bacteria such as 
Elizabethkingia anophelis have developed mechanisms of resistance.3 One such mechanism is 
the creation of beta-lactamases, which function by hydrolyzing the lactam ring on beta-lactam 
antibiotics. This hydrolysis causes the beta-lactam antibiotic to become unable to bind and 
inhibit penicillin-binding proteins. Another mechanism for beta-lactam resistance is caused from 
the production of multiple variations of penicillin binding proteins (PBP). This variation in 
penicillin binding proteins can be characterized in Methicillin-resistant Staphylococcus aureus 8 
and Actinobacteria species. 9 These variations cause antibiotic resistance by significantly 
lowering the binding affinity of beta-lactams to the new penicillin binding proteins.8,9 This 
causes beta-lactams to be ineffective at inhibiting the penicillin binding proteins making 
treatment ineffective. There are currently no classified novel penciling binding proteins 
identified in E. anophelis, but it is still something to consider when examining putative PBP. 
Another form of antibiotic resistance is the expression of efflux pumps. Efflux pumps function to 
transport foreign martial and cellular components outside of the cytoplasm or outside the cell. 
This allows for the excretion of beta-lactam antibiotics from the periplasmic space.10 Li et al. 
(1994) showed that Pseudomonas aeruginosa could remove hydrophilic beta-lactam antibiotics 
by measuring the cellular concentration of the hydrophilic antibioitc azlocilin at 20 minute time 
intervals. The concentration was measured by using dry cell mass to determine the molarity of 
the antibiotic in the cell. They found that over time the concentration in the cell decreased at a 
steady rate even in strains with low beta-lactam production.10 Li et al. later performed a similar 
experiment on a low beta-lactamase producing and a drug-hypersusceptible mutant known as 
K799/61. This experiment followed the same procedure of the original experiment and had 
similar results, which helped to further confirm their original findings by demonstrating that cells 
lacking beta-lactamases could provide some form of antibiotic resistant mechanism by increasing 
the expression of efflux pumps.11 Pages et al. (2009) also showed that the introduction of efflux 
pumps into Klebsiella pneumoniae caused increased antibiotic resistance to cefoxitin. This was 
done by using a Klebsiella pneumoniae strain that had a genome lacking the two characterized 
bet-lactamases of TEM- and AmpC-. After confirming the absence of these beta-lactamases they 
performed an immunodetection analysis of efflux pumps in the cell grown under antibiotic 
conditions. This immuodetection found that there were multiple efflux pumps being produced by 
the cells and that they existed in higher quantities compared to normal conditions. According to 
pages, this finding suggests that efflux pumps cause these antibiotic susceptible strain to be 
antibiotic resistant.  
Elizabethkingia anopheles expresses three characterized  beta-lactamases known as GOB, 
CME1, and BlaB. 15, 16 However, besides from these beta-lactamases there is very little 
information known about Elizabethkingia anophelis and the regulation of gene expression under 
antibiotic pressures is not understood. It has been predicted by whole genome sequencing that 
Elizabethkingia anophelis carries 19 β-lactamases, including 16 putative, four metallo-β-
lactamases (MBLs), two of which are putative, four putative penicillin-binding proteins and 13 
putative RND efflux pump proteins13,14. In this thesis, I will be examining all three of these 
pathways in order to investigate changes in expression of beta-lactamases, peptidoglycan 
synthesis and efflux pumps. I hypothesize that the expression of genes in the related three 
pathways will differ between exposures to beta-lactam antibiotics. In order to test the change in 
gene expression we examined the change in mRNA counts in Elizabethkingia anophelis under 
standard growth conditions and compared the mRNA counts under exposure to imipenem and 
cefotaxime. The three mechanisms mentioned above were specifically chosen because they are 
potentially involved in antibiotic resistance. We found that there was a change in expression 
among cefotaxime and imipenem in all pathways. 
 
Methods 
 In order to test this hypothesis Elizabethkingia anophelis R26 was grown in three 
separate 20mL cultures. A single colony was inoculated into 20mL of Mueller-Hinton broth 
(MHB) and grown over night at 37°C with shaking at 200rpm. After being allowed to grow 
the cultures were then diluted to an optical density at 600nm (OD600) of 0.1 and allowed to grow 
at 37°C to mid exponential phase (OD600 = 0.8).  They were then exposed to the relevant 
antibiotic for 20 minutes. The first culture contained no antibiotics and served as the negative 
control for the experiment. The second culture contained MHB and had 2ug/ml of imipenem 
added. Finally the last culture contained MHB media and had 4ug/ml cefotaxime added. After 
the cultures were grown the total RNA was extracted and purified. After purification the RNA 
was then shipped to the Macrogen Company (Rockvill, MD) for pair end sequencing. After 
receiving the paired end RNA sequences they were placed into the Rockhopper program in order 
to pair together the RNA sequences. 18,19 This helped to determine the total numbers of genes 
present in the genome as well as the total number of mRNA counts for each gene. The total 
mRNA count for the control sample was then compared to the antibiotic grown E. anophelis in 
order to show the fold change in transcription. We determined that any gene that had over 30 
total mRNA counts between the three cultures and had a fold change of 1.5 or higher were 
relevant changes. Once this information was determined the bacterial genome was entered into 
the KEGG automated annotation program in order to show the gene locations in the pathways of 
Elizabethkingia anopholies. 20 This information was then used to show the fold change of genes 
within the peptidoglycan biosynthesis, efflux pump and the beta-lactamase pathway under 
antibiotic conditions.  
 
Results 
 Elizabethkingia anophelis produce 15 proteins that are involved in the peptidoglycan 
biosynthesis pathway. All of these proteins are considered putative because they have been 
identified only through sequence identification. Regardless, these 14 putative genes were found 
at open reading frames (ORF) 187, 275, 269, 644, 646, 928, 995, 1250, 2285, 2284, 2287, 2288, 
and 3373. The putative enzyme name, fold change, and operons for each ORF can be found in 
table 1. These genes were found to span nearly the entire pathway (Figure 1). The fold change 
for all proteins can be found in figure 2. Out of the 14 putative genes there were 5 genes (ORF. 
187, 646, 995, 1250, and 3396) that encoded for the penicillin binding protein D-alanyl-D-
alanine carboxypeptidase17 in the pathway and are highlighted in yellow in table 1. D-alanyl-D-
alanine carboxypeptidase can be found at ORFs 187, 646, 995, 1250, and 3386. Under 
cefotaxime conditions, ORF 1250 was the only gene to have a relevant positive fold change 
(+1.6). This fold change lead to a +286 mRNA count increase compared to control conditions. 
There was also relevant fold change decrease at ORFs 187 and 646 (-1.6 and -2.6) following 
exposure to cefotaxime. The fold change decrease at ORFs 187 & 646 lead to a total decrease of 
-121 counts. Both the increase and decrease in mRNA count lead to an overall mRNA count 
increase of +165 for the putative D-alanyl-D-alanine carboxypeptidase genes. 
Under imipenem conditions there was only one relevant positive fold change at ORF 995 
and no relevant negative fold changes. This change at ORF 995 changed the mRNA count from 
10 to 17 and caused a total mRNA count increase of +7.  
Table 1: mRNA fold change for peptidoglycan synthesis pathway with operons. mRNA counts too low for 
relevance are in blue, fold change increases are in green, and fold change decreases are in orange. Relevant 
proteins are in yellow 
 
 
ORF Gene Description 
mRNA 
Count 
Control 
mRNA 
Counts 
Cefotax 
mRNA 
Counts 
Imipenem 
Fold 
Change 
Cefotax 
Fold 
Change 
Imipenen Operonic? 
187 D-alanyl-D-alanine carboxypeptidase (EC 3.4.16.4) 294 189 350 -1.6 1.2 187, 188 
269 
UDP-N-acetylglucosamine 1-carboxyvinyltransferase 
(EC 2.5.1.7) 29 13 21 -2.2 -1.4 268, 269 
275 
UDP-N-acetylenolpyruvoylglucosamine reductase 
(EC 1.1.1.158) 72 36 71 -2.0 -1 None 
644 
Prolipoprotein diacylglyceryl transferase (EC 2.4.99.-
) 69 32 64 -2.2 -1.1 644, 645, 646 
646 D-alanyl-D-alanine carboxypeptidase (EC 3.4.16.4) 34 13 41 -2.6 1.2 644, 645, 646 
928 
UDP-N-acetylmuramoylalanyl-D-glutamyl-2,6-
diaminopimelate--D-alanyl-D-alanine ligase (EC 
6.3.2.10) 570 748 513 1.3 -1.1 None 
995 D-alanyl-D-alanine carboxypeptidase (EC 3.4.16.4) 10 6 17 -1.7 1.7 994, 995 
1250 D-alanyl-D-alanine carboxypeptidase (EC 3.4.16.4) 463 749 373 1.6 -1.2 1250, 1251 
2285 
UDP-N-acetylmuramoylalanine--D-glutamate ligase 
(EC 6.3.2.9) 69 53 132 -1.3 1.9 
2284, 2285,2286,2287, 
2288,2289 
2284 
Phospho-N-acetylmuramoyl-pentapeptide-transferase 
(EC 2.7.8.13) 76 39 62 -1.9 -1.2 
2284, 2285,2286,2287, 
2288,2289 
2283 
UDP-N-acetylmuramoylalanyl- D-
glutamate : 2,6-diaminopimelate ligase 369 366 293 -1 -1.3 2280, 2281, 2282, 2283 
2287 
UDP-N-acetylglucosamine--N-acetylmuramyl-
(pentapeptide) pyrophosphoryl-undecaprenol N-
acetylglucosamine transferase (EC 2.4.1.227) 1908 2971 1574 1.6 -1.2 
2284, 2285,2286,2287, 
2288,2289 
2288 UDP-N-acetylmuramate--alanine ligase (EC 6.3.2.8) 5903 8416 3858 1.4 -1.5 
2284, 2285,2286,2287, 
2288,2289 
2954 Undecaprenyl-diphosphatase (EC 3.6.1.27) 6 6 10 2.5 3.5 
2952, 2953, 2954,  
2955, 2956 
3373 D-alanine--D-alanine ligase (EC 6.3.2.4) 29 17 40 -1.7 1.4 3373, 3374, 3375 
3396 D-alanyl-D-alanine carboxypeptidase (EC 3.4.16.4) 21 23 16 1.1 -1.3 None 
  
Figure 1: Peptidoglycan synthesis pathway proteins recognized by KEGG are highlighted green with ORF in 
boxes. Boxes with enzyme code were not found in gene list. Enzymes marked with NA were recognized by 
KEGG but not found in gene list. Name of gene next to the ORF box.  
Adapted from: http://www.genome.jp/kegg-
bin/show_pathway?org_name=eao&mapno=00550&mapscale=&show_description=hide  
Within the KEGG antibiotic resistance pathway there are seven proteins that produced 
putative RND efflux pumps. All seven of these proteins were located at the same position in this 
pathway and are labeled as RND efflux pumps. The genes that encode for putative RND efflux 
pumps at ORFs 811, 1584, 1821, 2867, 2868, 2869, and 3436 (Table 2). Under cefotaxime 
conditions there were relevant fold change increases in ORFs 1821, 2868, 2869, and 3436 and no 
relevant fold change decreases when compared to the control. ORF 1821 encodes for a putative 
RND multidrug efflux transporter Acriflavin resistance protein. The putative multi-drug 
transporter we observed a fold change increase of +1.6 and changed the mRNA count from 9 to 
14 (+5). ORF 2868 encoded for a putative RND efflux system, inner membrane transporter 
cmeB. For the putative cmeB transport system we observed a fold change increase of +1.6 and 
changed the mRNA count from 98 to 156 (+58). ORF 2869 encoded for a putative efflux 
transporter, RND family, MFP subunit. For the putative subunit we observed a fold change 
increase of +4.4 and changed the mRNA count from 1299 to 2067 (+768). Finally, ORF 3436 
endcoded for a putative heavy metal RND efflux outer membrane protein, czcC family. For the 
putative czcC outer membrane protein we observed a fold change increase of +1.8 and had an 
mRNA count change from 207 to 910 (+703). All 4 of these genes combined lead to a total 
relevant mRNA increase of +1534.  
Under imipenem conditions, there was a relevant fold change increase in ORFs 811 and 
1821. ORF 2867 also had a fold change increase greater than 1.5 levels, but had mRNA counts 
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Figure 2: Fold change graph for peptidoglycan synthesis pathway proteins.  
Table 2: mRNA fold change chart for RND efflux pumps production with operons. mRNA counts too low for 
relevance are in blue, fold change increases are in green, and fold change decreases are in orange 
Figure 3: Fold change graph RND efflux pumps.  
were too low to be considered relevant. For ORF 811 (putative cmeB transporter) we observed a 
fold change increase of +1.8 and changed the mRNA count from 9 to 16 (+7). For ORF 1821 
(putative multi-drug pump) we observed an increased fold change of +1.6 and changed the 
mRNA count from 9 to 14 (+5). There was also relevant fold decrease at ORFs 2869. For ORF 
2869 (putative MFP subunit) we observed a fold change decrease of -1.6 and changed the mRNA 
from 1299 to 800 (-499). When examining the mRNA change of the up and down regulated 
genes it can be seen that ORF 2869 had a total mRNA count drop by -499. While the increases 
from ORFs 811 and 1821 only had a total mRNA increase of +13. This leads to an overall 
decrease in mRNA count of -486 (Figure 3). 
 
ORF Gene Description 
mRNA 
Count 
Control 
mRNA 
Counts 
Cefotax 
mRNA 
Counts 
Imipenem 
Fold 
Change 
Cefotax 
Fold 
Change 
Imipenen Operonic? 
811 RND efflux system, inner membrane transporter (CmeB) 9 13 16 1.4 1.8 808, 809, 810, 811 
1584 efflux transporter, RND family, MFP subunit 726 1025 590 1.4 -1.2 1584, 1585, 1586 
1821 
RND multidrug efflux transporter; Acriflavin resistance 
protein 9 14 14 1.6 1.6 1820, 1821 
2867 
RND efflux system, outer membrane lipoprotein, NodT 
family 3 6 10 2 3.3 2867, 2868, 2869 
2868 RND efflux system, inner membrane transporter CmeB 98 156 93 1.6 -1.1 2867, 2868, 2869 
2869 efflux transporter, RND family, MFP subunit 1299 2067 800 1.6 -1.6 2867, 2868, 2869 
3436 
Heavy metal RND efflux outer membrane protein, CzcC 
family 207 910 301 4.4 1.4 3434, 3435, 3436 
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 In addition, 15 proteins produced putative beta-lactamase products. These proteins are found at 
ORFs 29, 194, 339, 503, 519, 605, 666, 1010, 1103, 1724, 1915, 1990, 2536, 2959, and 3527. All 
of these proteins are considered putative except for those located at ORF 503, 1915, and 2054, 
which encode for CME, blaB and GOB respectively. Under cefotaxime conditions there were 
relevant positive fold changes at ORF 605, 1103 and 1915 (blaB). For ORF 605 we observed a 
fold change increase of 1.7 and changes the mRNA count from 471 to 797 (+320). For ORF 1103 
we observed a fold change increase of +1.7 and changes mRNA count from 63 to 106 (+43). For 
BlaB (ORF 1915) we observed a fold change increase of +1.5 and changed from 89 to 144 (+55). 
There were also relevant fold change decreases in ORFs 519, 666, 1010 (putative TLA) and 2054 
(GOB). For ORF 519 we observed a negative fold change of -2.5 and changed the mRNA count 
from 48 to 19 (-29). Fpr Orf 666 we observed a fold change decrease of -3.8 and changed the 
mRNA count from 930 to 242 (-688) while the putative TLA (1010) we observed a fold change 
decrease of -2.1 and changed mRNA count from 71 to 34 (-37). Finally, for GOB (ORF 2054) we 
observed a fold change decrease of -2.2 and changed the mRNA count from 248 to 112 (-136). 
When examining all these relevant proteins it can be seen that there is a total mRNA count 
decrease -435. However when examining only the total mRNA change between blab, CME, and 
GOB there was a total decrease of -118 of known beta-lactamases. 
 Under imipenem conditions there was relevant positive fold change at ORF 605, 666, 
1724, GOB and 2959. For ORF 605 we observed a fold change increase of +1.7 and changed the 
mRNA count from 471 to 797 (+326). For ORF 666 we observed a fold change increase of +2.5 
and changed the mRNA count from 930 to 2332 (+1402). For ORF 1724 we observed a fold 
change increase of +2.5 and changed the mRNA count from 14 to 35 (+21). For GOB (ORF 
2054) we observed a fold change increase of +1.6 and changed the mRNA count from 249 to 397 
(+149). Finally, for ORF 2959 we observed a fold change increase of +2.4 and changed the 
mRNA count from 5 to 12 (+7). There were also relevant fold change decreases at ORF 
503(CME) and ORF 1103. For CME we observed a fold change decrease of -2.2 and changed the 
mRNA count from 71 to 32 (-39). Then for ORF 1103 we observed a fold change decrease of -
1.5 and changed the mRNA count from 63 to 42 (-21). The combination of the up and down 
regulated genes leads to a total mRNA change of +1821, with the majority of the changes 
coming from ORF 605 and ORF 666. All fold change for all beta-lactamases can be seen in 
figure 4. 
 
ORF Gene Description 
mRNA 
Count 
Control 
mRNA 
Counts 
Cefotax 
mRNA 
Counts 
Imipenem 
Fold 
Change 
Cefotax 
Fold 
Change 
Imipenen Operonic? 
29 Beta-lactamase (EC 3.5.2.6) 7 6 9 -1.2 1.3 None 
194 Beta-lactamase (EC 3.5.2.6) 116 132 109 1.1 -1.1 None 
339 Beta-lactamase (EC 3.5.2.6) 1 1 1 1 1 338, 339 
503 Beta-lactamase (CME) 71 56 32 -1.3 -2.2 502, 503, 504, 505 
519 Beta-lactamase (EC 3.5.2.6) 48 19 37 -2.5 -1.3 519, 520, 521 
605 Beta-lactamase (EC 3.5.2.6) 471 797 685 1.7 1.5 None 
666 beta-lactamase domain protein 930 242 2332 -3.8 2.5 666, 667 
1010 Beta-lactamase  (Putative TLA) 71 34 72 -2.1 1 None 
1103 beta-lactamase domain protein 63 106 42 1.7 -1.5 1101, 1102, 1103 
1724 Beta-lactamase (EC 3.5.2.6) 14 12 35 -1.2 2.5 None 
1915 Beta-lactamase (blaB) 89 144 69 1.5 -1.3 None 
1990 Metallo-beta-lactamase superfamily protein PA0057 1 3 3 3 3 1988, 1989, 1990 
2054 Metalo Beta-Lactamase precursor (GOB) 248 112 397 -2.2 1.6 
2052, 2053, 2054, 
2055, 2556, 2557, 
2558, 2559, 2560  
2536 Beta-lactamase 16 17 12 1.1 -1.3 None 
2959 
AmpG protein, beta-lactamase induction signal 
transducer 5 6 12 1.2 2.4 2959, 2960 
3527 Beta-lactamase (EC 3.5.2.6) 24 19 21 -1.2 -1.1 3527, 3528 
 
Table 3: mRNA fold change chart for Beta-lactamase production with operons. mRNA counts too low for 
relevance are in blue, fold change increases are in green, and fold change decreases are in orange 
 Discussion 
Elizabethkingia is an important emerging pathogen whose mechanisms for antibiotic 
resistance are not well characterized. In order to test the hypothesis of there being unique 
regulation of genes under different antibiotic conditions we examined the fold change in relevant 
gene expression in both the cefotaxime and imipenem cultures. With the information gathered 
from this experiment it appears to support the hypothesis that E. anopheles expresses distinct 
responses to each antibiotic, and we were able to identify ORF666, a putative MBL as potentially 
playing an important role in resistance to imipenem.  
In the peptidoglycan synthesis pathway under cefotaxime conditions the production of 
the putative D-alanyl-D-alanine carboxypeptidase protein we observed a down regulation of two 
ORFs (187 and 646) and an up regulation of one ORF (1250). This regulation led to an overall 
mRNA count increase of +156 with ORF 1250 having a mRNA increase of +285. This total 
increase could be relevant because it may imply that the cell requires greater peptidoglycan 
synthesis. This could be due to beta-latamases not disrupting all beta-lactams and causing some 
to enter the cell, causing some PBP to be made inactive. If PBP were inhibited the cell would 
need to increase synthesis of PBP in order to compensate for the loss. It could also imply that the 
Fold change chart Beta-Lactamases
-3
-2
-1
0
1
2
3
OR
F 2
9
Or
f 1
94
Or
f 3
39
Or
f 5
03
OR
F 5
19
OR
F 6
05
 O
RF
66
6
 O
RF
 1
01
0
OR
F 1
10
3
 O
RF
 1
72
4
 O
RF
 1
91
5
 O
RF
 1
99
0
OR
F 2
05
4
OR
F 2
53
6
OR
F 2
95
9
OR
F 3
52
7
ORF
Fo
ld
 C
h
an
ge
Cefotaxime fold change
Imipenem fold change
-
Figure 4: Fold change graph Beta-lactamases. X-Axis is ORF number Y-Axis is fold change 
cell is switching to more efficient peptidoglycan synthesis mechanism that could have decreased 
binding affinity to cefotaxime. It is also possible that these changes in regulation could be due to 
the cell having differing growth that causes the cell progresses slower or faster through the 
growth cycle. However, without further testing it cannot be known why this regulation occurs. 
But, while we may not be able to determine the reason for the up regulation at this time we can 
see that the response under imipenem is very different. Under imipenem there was only relevant 
up regulation of one ORF (995) and it lead to an overall mRNA count of +7. In comparison to 
the cefotaxime conditions, the mRNA change in imipenem is roughly 22 times smaller than the 
change under cefotaxime.  This difference change may suggest that under imipenem conditions 
there is not a large need for increased peptidoglycan. One explanation for this could due to the 
production of more effective beta-lactmase functionality, allowing the cells to grow at a rate that 
is more comparable to the control conditions. An alternative explanation could be that the 
imipenem culture had its exponential phase slowed by the presence of imipenem and is still 
synthesizing large amounts of peptidoglycan, while the cefotaxime may not.  However, the 
addition of the antibiotic when all cultures were at an OD600 of 0.8 argues against this. The 
redundant nature of the gene could be due to a variety of reasons. One reason could be that each 
of these putative D-alanyl-D-alanine carboxypeptidase have different specificity or affinities that 
are activated by signaling pathways in the cell. This could possibly explain the difference in 
regulation amoung the two antibiotic enviorments. It’s also possible that the redundancy is 
caused by the cell requiring different effective D-alanyl-D-alanine carboxypeptidase during each 
cell cycle, causing alternate expression at each phase of cell growth. One possible method of 
testing this hypothesis could be done by performing a real time PCR to determine mRNA count 
changes. 
 The production of RND efflux pump proteins we observed a similar trend of regulation to 
that of peptidoglycan synthesis with cefotaxime causing only up regulation and the imipenem 
causing a combination of up and down regulation. Under cefotaxime there was only up 
regulation leading to a total mRNA increase of +1,534. This increase in mRNA transcripts could 
suggest that the production of RND efflux pumps may be stimulated by the presence of 
cefotaxime. However, more research is required in order to confirm this.  Also, according to the 
proteins name at ORF 2869 & 3436 these proteins encode for both inner and outer membrane 
pumps. This large increase in both inner and outer membrane pumps could suggest that 
cefotaxime causes the cell to up regulate pumps to remove cefotaxime from the periplasmic 
space. Imipenem treated cells have opposite regulation with a total mRNA count decrease of -
687 and both ORF 2869 & 3436 being down regulated. This change in relevant mRNA count is 
interesting because when comparing cefotaxime and imipenem it can be seen that relevant gene 
regulation caused a difference in mRNA count by 2,212. This number is relevant and could 
imply that the proteins at ORF 2869 & 3436 are possibly inducible and relevant for antibiotic 
resistance, however in vivo work is needed to confirm this possibility. This change in regulation 
was in accordance with the information presented by Li et al. (1994) when they predicted that 
hydrophilic antibiotics would be excreted from the cell due to the increase in production of efflux 
pumps. The data shows that under cefotaxime conditions (a hydrophilic antibiotic)21 production 
of efflux pumps increased significantly, while under imipenem conditions (a hydrophobic 
antibiotic)22 efflux pump production decreased. Another important factor to consider is that both 
of these proteins normally express large number of mRNA counts under standard conditions. 
This could imply that these pumps have important physiological functions that are not related to 
antibiotic resistance. However, more research is required in order to confirm this. 
 Finally, beta-lactamase production had an overall decrease of -118 while under 
cefotaxime conditions. Of the known beta-lactamases CME did not have relevant change, blaB 
increased, and GOB and the putative TLA decreased. BlaB had an increased mRNA count of +43 
while GOB had a mRNA decrease of -137. The change in these known beta-lactamases suggests 
that the up regulation blaB is due to the introduction by cefotaxime. This could be due to blaB 
being more effective at hydrolyzing cefotaxime or could simply be caused by some condition of 
cefotaxime inducing blaB. This response is coincides with research Boschi (2000) that found that 
there was a putative correlation between cephalosporins and blaB.23 Also, although is not 
characterized it did have a TLA relevant mRNA decrease of -37. Besides from TLA and the 
known beta-lactamases a putative beta-lactamase at ORF 666 had relevant mRNA decrease of -
688. This mRNA change is the greatest out of all of the genes in the beta-lactamase chart and 
could be a beta-lactamase or a protein important to beta-lactamases due to its large mRNA 
changes. Under imipenem conditions GOB is upregulated and CME is down regulated. This 
increase in GOB is possibly induced by an environment factor created from imipenem. For all 
genes under imipenem there was a total relevant mRNA increase of +1821. There was also a 
relevant increase once again at ORF 666 where it had a total mRNA change of +1402. This 
mRNA change is extremely large in comparison to all other genes in this pathway. It possible 
that this putative protein may have some relation to GOB since its regulation under each 
antibiotic mimicked the direction of GOB in both cases. Sequence identity suggests that the 
protein is a putative metallo beta-lactamase. If this protein actually encodes for a beta-lactamase 
the up regulation with GOB and ORF 666 could imply that some cellular condition created by 
imipenem could cause selection for metallo beta-lactamases 
 
Conclusions and future directions 
The data suggests that E.anophelis uses different mechanisms when interacting with 
specific antibiotics. This is because when examining relevant fold change genes there are drastic 
differences. In the peptidoglycan synthesis pathway cefotaxime exposed cells had a 22 fold 
greater up regulation compared to imipenem exposed cells. In the RND efflux pump pathway 
there was a difference of 2212 mRNA count change between relevant genes. Finally, beta-
lactamase seemed to be produced in greater numbers when exposed to cefotaxime and imipenem. 
GOB specifically seemed to be up regulated by the presence of imipenem but down regulated 
under cefotaxime. This in conjunction with the putative beta-lactamase at ORF 666 lead to a 
2000+ mRNA count change among beta-lactamases. When reacting with cefotaxime the data 
suggests that E. anophelis may have increased production of RND efflux pumps and 
peptidoglycan synthesis products. While significantly decreasing the production of beta-
lactamases except BlaB. However, when reacting to imipenem it is likely that Elizabethkingia 
anophelis responds with a down regulation of RND efflux pump but increases the production 
peptidoglycan synthesis products and begins to produce greater number of GOB beta-lactamases 
and an unknown putative metalo beta-lactamase at ORF 666.  
More research is required to test the change in response to beta-lactam antibiotics. I 
would recommend attempting to grow Elizabethkingia anophelis R26 cultures that have relevant 
genes knocked out. This would help to show the significance or insignificance of the gene under 
each condition. The first gene to look at would be the putative metalo-beta-lactamse at ORF 666. 
This change in resistance could be tested by transforming this putative metallo-beta-lactamase 
into E. coli or another bacterial species. Then observe if bacteria were able to grow under 
imipenem conditions and not under cefotaxime conditions. If the bacteria have specified 
resistance it would suggest ORF 666 is a novel and functional metallo-beta-lactamase. 
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